© The Author 2006. Published by Oxford University Press.
CORRESPONDENCE |
Re: Randomized Double-Blind Factorial Trial of Three Treatments to Reduce the Prevalence of Precancerous Gastric Lesions
Affiliations of authors: Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN (RM, MBP, MCC, PC); School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ETHF); Department of Pathology, Universidad del Valle, Cali, Colombia (LEB, JCB)
Correspondence to: Pelayo Correa, MD, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, 2215 Garland Ave., 1030 MRB IV, Nashville, TN 37232-0252 (e-mail: pelayo.correa@vanderbilt.edu).
| The first 10% of the full text of this article appears below. |
We congratulate You et al. (1) for the successful completion of their chemoprevention trial. Their results have clear implications for gastric cancer prevention. As emphasized by the authors, all available reports conclude that curing Helicobacter pylori infection is a promising strategy to control gastric cancer. Previously, we supplied the authors with raw data from our
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C.-W. Lee, B. Rickman, A. B. Rogers, Z. Ge, T. C. Wang, and J. G. Fox Helicobacter pylori Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice Cancer Res., May 1, 2008; 68(9): 3540 - 3548. [Abstract] [Full Text] [PDF] |
||||
